Boundless Bio, Inc.
Statements
Cash Flow
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | -1,473.8% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 28.0% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 190.2% | – | – | – | – | – | – | – | |
| – | – | – | – | – | -106.6% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 44.1% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 172.6% | – | – | – | – | – | – | – | |
| – | – | – | – | – | 10.7% | – | – | – | – | – | – | – | |
| – | – | – | – | – | -1,290.4% | – | – | – | – | – | – | – | |
| – | – | – | – | – | -1,517.9% | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.